Clinical Trial Record

Return to Clinical Trials

Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy


2021-02-01


2023-12-07


2024-01-07


48

Study Overview

Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy

Perioperative immunologic signatures can predict the risk of postoperative complications. The results will be puplished as two smanuscripts. The manuscript will focus on preoperative immunologisk data,the second manuscript will include both pre- and postoperative data.

OBJECTIVE Establish evidence for perioperative immunologic risk stratification of patient's risk for clinically postoperative inflammatory complications as a basis for future mechanism-based intervention studies. Combining detailed immune assessment from cell-receptors to cell expression, cytokines, and complications with a temporal aspect is innovative and provides highly warranted novel multidimensional immunological insight. METHODS Adult patients scheduled for PD on the suspicion of pancreatic cancer excluding patients receiving immunomodulating treatment 1 month properatively and/or autoimmune diseases. Patients scheduled for simultaneous procedures on major blood vessels, and/or adjacent organs (spleen, liver) are also not included. Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory instability hindering procedure completion and/or concomitant surgery on major blood vessels, spleen, or liver, are excluded post-inclusion and will not be part of the primary analysis. Patients eligible for inclusion will be identified before their appointment at the Gastrosurgical Dept., Rigshospitalet which is the largest DK and North-European center with about 200 PD/yr annually. Primary outcome: Persistent postoperative hypotension, defined as need for vassopressor infussion on the morning after surgery to maintain middle arterial bloodpressure >65 mmHg

  • Pancreas Cancer
  • DIAGNOSTIC_TEST: blood sample
  • H-17024315

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2021-01-31  

N/A  

2025-04-02  

2021-02-25  

N/A  

2025-04-06  

2021-03-01  

N/A  

2025-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Occurrence of persistent postoperative hypotension

Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.

DIAGNOSTIC_TEST: blood sample

  • Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory mol
: No occurrence of persistent postoperative hypotension

Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.

DIAGNOSTIC_TEST: blood sample

  • Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory mol
Primary Outcome MeasuresMeasure DescriptionTime Frame
Number of patients with persistent postoperative hypotension (<65 mmHg) after surgeryNeed for vasopressor infusion (noradrenaline) to maintain middle arterial blood pressure >65 mmHg, the morning after pancreaticoduodenectomy.24 hours
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Number of patients with infectionEx. surgical site infection, pneumonia, sepsis, etc, based upon international criteria (eg. center for disease control)30 days
Number of patients with occurrence (yes/no) of systemic inflammatory response syndrome (SIRS) at any time during the first 30 daysSIRS defined as two or more of either of the following four criteria: i) temperature <36°C or >38°C, ii) heart rate >90/min., iii) respiratory rate >20/min and/or iv) white blood cell count (WBC) <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³) or ≥10% bands neutrophils.30 days
Number of patients with severe clinical intra- and postoperatove complicationsComplications assessed by Clavien-Dindo classification and Comprehensive Clinical complication Index (CCI) ( (i.e. anastomotic leakage, reoperation, thrombosis, bleeding, etc.)30 days
Number of patients with severe clinical intra- and postoperative complicationsComplications assessed by SOFA score including single organ system deviation30 days
Number of patients with severe perioperative physiological deviationsFrequency og physiological deviation Monitored by WARD-clinical support system (i.e hypotension, desaturation, tachycardia, etc.).30 days
Number of patients with development of delirium after surgeryDevelopment of delirium measured with the 3D-CAM score7 days

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Scheduled for PD on the suspicion of pancreatic cancer
  • Patients able to follow standardised surgical procedure including TIVA anaesthesia with epidural

  • Exclusion Criteria:

  • Bilirubin >100 µmol/ltr
  • Patients receiving immunomodulating treatment 1 month properatively and/or autoimmune diseases and patients non-cenacerous cystic lessions
  • Patients scheduled for simultaneous procedures on major arterial blood vessels, and/or adjacent organs (spleen, liver)
  • Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory instability hindering procedure completion and/or concomitant surgery on major arterial blood vessels, spleen, or liver, are excluded post-inclusion and will not be part of the primary analysis
  • ongoing treatment with glucocortocoid, anti-tnf-alpha etc.
  • patients diagnosed with rheumatological diseases, IBD or chronic infection (eg. HIV)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • STUDY_CHAIR: Eske K Aasvang, DMSci, Rigshospitalet, Denmark

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available